Mediwound (NASDAQ:MDWD) is set to post its quarterly earnings results before the market opens on Thursday, November 14th. Analysts expect Mediwound to post earnings of ($0.15) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.
Mediwound (NASDAQ:MDWD) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. Mediwound had a negative return on equity of 156.56% and a net margin of 70.54%. The business had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $7.03 million. On average, analysts expect Mediwound to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of MDWD stock opened at $2.88 on Wednesday. The business’s 50 day simple moving average is $2.98 and its 200 day simple moving average is $3.47. Mediwound has a one year low of $2.55 and a one year high of $6.09. The stock has a market capitalization of $81.54 million, a PE ratio of -5.88 and a beta of 0.48. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.13 and a quick ratio of 3.99.
Several analysts recently commented on the company. Zacks Investment Research upgraded Mediwound from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a report on Wednesday, October 30th. Oppenheimer reduced their target price on Mediwound from $15.00 to $7.00 and set an “outperform” rating on the stock in a report on Wednesday, August 14th. HC Wainwright assumed coverage on Mediwound in a report on Monday, August 5th. They issued a “buy” rating and a $5.50 target price on the stock. Finally, ValuEngine upgraded Mediwound from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Read More: Why is the ROA ratio important?
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.